Gene · 6571
SLC18A2: solute carrier family 18 member A2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SLC18A2: solute carrier family 18 member A2. Genes, record 6571. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6571
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q05940 | Synaptic vesicular amine transporter | 514 | 32 | Ensembl, GeneID, HGNC |
Source UniProt
Patents37
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4770680 A1 | 2026-07-08 | 16 | Q05940 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 64098 | Q05940 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 1392 | Q05940 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 4033 | Q05940 | Espacenet |
| JP 2025118609 A | 2025-08-13 | 4 | Q05940 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 4033 | Q05940 | Espacenet |
| WO 2025036766 A1 | 2025-02-20 | 2 | Q05940 | Espacenet |
| EP 4506468 A1 | 2025-02-12 | 2 | Q05940 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 1392 | Q05940 | Espacenet |
| US 12083116 B2 | 2024-09-10 | 5 | Q05940 | Espacenet |
1 to 10 of 37
See all 37 patentsDrugs15
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BENZPHETAMINE | CHEMBL3545985 | Synaptic vesicular amine transporter inhibitor | INHIBITOR | ChEMBL |
| BENZPHETAMINE HYDROCHLORIDE | CHEMBL3544906 | Synaptic vesicular amine transporter inhibitor | INHIBITOR | ChEMBL |
| DESERPIDINE | CHEMBL1200515 | Synaptic vesicular amine transporter inhibitor | INHIBITOR | ChEMBL |
| DEUTETRABENAZINE | CHEMBL3137326 | Synaptic vesicular amine transporter inhibitor | INHIBITOR | ChEMBL |
| DEXTROAMPHETAMINE | CHEMBL612 | Synaptic vesicular amine transporter inhibitor | INHIBITOR | ChEMBL |
| DEXTROAMPHETAMINE ADIPATE | CHEMBL1200782 | Synaptic vesicular amine transporter inhibitor | INHIBITOR | ChEMBL |
| DEXTROAMPHETAMINE SACCHARATE | CHEMBL3989844 | Synaptic vesicular amine transporter inhibitor | INHIBITOR | ChEMBL |
| DEXTROAMPHETAMINE SULFATE | CHEMBL3544971 | Synaptic vesicular amine transporter inhibitor | INHIBITOR | ChEMBL |
| LISDEXAMFETAMINE | CHEMBL1201222 | Synaptic vesicular amine transporter inhibitor | INHIBITOR | ChEMBL |
| LISDEXAMFETAMINE DIMESYLATE | CHEMBL1201178 | Synaptic vesicular amine transporter inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 15
See all 15 drugsTrials173
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07601516 | DEUTETRABENAZINE | PHASE4 | ClinicalTrials.gov | |
| NCT07111988 | VALBENAZINE | PHASE2 | ClinicalTrials.gov | |
| NCT06967857 | DEXTROAMPHETAMINE SULFATE | PHASE2 | ClinicalTrials.gov | |
| NCT06847399 | LISDEXAMFETAMINE DIMESYLATE | PHASE2 | ClinicalTrials.gov | |
| NCT06771323 | VALBENAZINE | PHASE2 | ClinicalTrials.gov | |
| NCT06312189 | VALBENAZINE | PHASE3 | ClinicalTrials.gov | |
| NCT05957055 | LISDEXAMFETAMINE | PHASE2 | ClinicalTrials.gov | |
| NCT05790239 | DEXTROAMPHETAMINE | PHASE2 | ClinicalTrials.gov | |
| NCT05654870 | VALBENAZINE | PHASE3 | ClinicalTrials.gov | |
| NCT05621174 | DEXTROAMPHETAMINE | ClinicalTrials.gov |
1 to 10 of 173
See all 173 trialsNIH grants2,143
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SLC18A2 papers | Newest fiscal year |
|---|---|---|---|
| T32ES012870 | Graduate and Postdoctoral Training in Environmental Health Science and Toxicology | 32 | 2025 |
| P30ES019776 | HERCULES: Exposome Research Center | 22 | 2025 |
| R01ES023839 | Vesicular modulation of dopamine neuron toxicity | 14 | 2025 |
| ZIANS003034 | Biomarkers of Catecholaminergic Neurodegeneration | 14 | 2025 |
| R01DA007418 | The Dopamine Synapse and Associative Learning | 11 | 2025 |
| ZIAMH002386 | Chemical Coding of Neurotransmission | 9 | 2025 |
| R01ES010563 | Mechanisms of Manganese Neurotoxicity | 7 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 6 | 2025 |
| ZIADA000522 | Preclinical medication development for stimulant use disorder | 6 | 2025 |
| P30ES005022 | Rutgers Center for Environmental Exposure and Disease (CEED) | 5 | 2025 |
1 to 10 of 2,143Source NIH's project files
See all 2,143 nih grantsPapers3,040
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of a shared blood-brain transcriptomic signature in Parkinson's disease using bioinformatic and network pharmacology approaches. | Neuroscience | 2026 | 42826760 | PubTator, text mining | PubMed |
| Molecular mechanisms of Microcystin-LR decreasing dopamine release by binding VPS35 and clinical correlation between Microcystin-LR exposure and Parkinson's disease. | J Environ Sci (China) | 2026 | 42822928 | PubTator, text mining | PubMed |
| Exploring the Potential Neurotoxic Links Between 6PPD/6PPD-Q and Parkinson's Disease Through Network Toxicology and Multi-Dimensional Bioinformatics Analysis. | Neurotox Res | 2026 | 42821203 | PubTator, text mining | PubMed |
| The mechanism underlying tardive dyskinesia: an exploratory test of the dopamine overactivity hypothesis using MRI imaging of midbrain neuromelanin. | Psychopharmacology (Berl) | 2026 | 42809103 | PubTator, text mining | PubMed |
| Stereoselectivity of pleiotropic monoamine transporter 2-benzoylpiperidine inhibitors and their potential application as novel pharmacological tools. | Biochem Pharmacol | 2026 | 42800567 | PubTator, text mining | PubMed |
| Dopaminergic Radiopharmaceutical Imaging in Parkinsonian Syndromes: From Molecular Targets to Clinical Decision-Making. | Pharmaceuticals (Basel) | 2026 | 42797415 | PubTator, text mining | PubMed |
| A Case Report: Successful Management of Mixed Tardive Syndrome With Combination Pharmacotherapy in a 19-Year-Old Female With Schizophrenia. | Clin Case Rep | 2026 | 42750933 | PubTator, text mining | PubMed |
| Neuromodulation therapies in the management of tardive dyskinesia: A scoping review. | Indian J Psychiatry | 2026 | 42725344 | PubTator, text mining | PubMed |
| Therapeutics candidates and repurposing strategies to target parkinson's disease pathology: current evidence and future directions. | Metab Brain Dis | 2026 | 42714656 | PubTator, text mining | PubMed |
| Deutetrabenazine in Hyperkinetic Movement Disorders: VMAT2 Modulation From Choreiform Disorders to Hyperkinetic Dystonic Syndromes. | J Cent Nerv Syst Dis | 2026 | 42682903 | PubTator, text mining | PubMed |
1 to 10 of 3,040
See all 3,040 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6571
GET https://conductscience.org/api/genes/v1/6571/patents?page=2